Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Down 79.3% in August

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) saw a large decline in short interest in August. As of August 31st, there was short interest totaling 340,186 shares, a decline of 79.3% from the August 15th total of 1,646,299 shares. Based on an average daily trading volume, of 786,030 shares, the days-to-cover ratio is currently 0.4 days. Currently, 39.3% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several research analysts recently weighed in on VBIO shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Friday, July 17th. Wall Street Zen upgraded Valion Bio, Inc. Common Stock to a “hold” rating in a research report on Saturday, September 5th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Valion Bio, Inc. Common Stock has a consensus rating of “Sell”.

Valion Bio, Inc. Common Stock Price Performance

Shares of NASDAQ:VBIO opened at $2.26 on Friday. The firm has a market cap of $2.01 million, a price-to-earnings ratio of -0.01 and a beta of 1.79. The firm has a fifty day moving average price of $6.58 and a 200 day moving average price of $16.38. Valion Bio, Inc. Common Stock has a fifty-two week low of $2.16 and a fifty-two week high of $80.19. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.86 and a current ratio of 1.11.

Valion Bio, Inc. Common Stock Company Profile

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.